Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors?

Jürg Gertsch* (Corresponding Author), Sharon Anavi-Goffer

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The cannabinoid type-2 G protein-coupled (CB2) receptor is an emerging therapeutic target for pain management and immune system modulation. In a mouse model of Alzheimer’s disease (AD) the orally administered natural product 4′-O-methylhonokiol (MH) has been shown to prevent amyloidogenesis and progression of AD by inhibiting neuroinflammation. In this commentary we discuss an intriguing link between the recently found CB2 receptor-mediated molecular mechanisms of MH and its anti-inflammatory and protective effects in AD animal models. We argue that the novel cannabimimetic MH may exert its beneficial effects via modulation of CB2 receptors expressed in microglial cells and astrocytes. The recent findings provide further evidence for a potential role of CB2 receptors in the pathophysiology of AD, spurring target validation and drug discovery.
Original languageEnglish
Article number135
Number of pages5
JournalJournal of Neuroinflammation
Volume9
DOIs
Publication statusPublished - 20 Jun 2012

Fingerprint

Cannabinoid Receptor CB2
Cannabinoid Receptors
Alzheimer Disease
Cannabinoids
Drug Discovery
Pain Management
G-Protein-Coupled Receptors
Biological Products
Astrocytes
Immune System
Anti-Inflammatory Agents
Animal Models

Keywords

  • Alzheimer’s disease
  • Cannabinoids
  • CB2 receptors
  • Endocannabinoid System
  • Magnolia grandiflora
  • Medicinal plant
  • Methylhonokiol

Cite this

Methylhonokiol attenuates neuroinflammation : a role for cannabinoid receptors? / Gertsch, Jürg (Corresponding Author); Anavi-Goffer, Sharon.

In: Journal of Neuroinflammation, Vol. 9, 135, 20.06.2012.

Research output: Contribution to journalArticle

@article{40a8330c46c24078aff7dad87a27587c,
title = "Methylhonokiol attenuates neuroinflammation: a role for cannabinoid receptors?",
abstract = "The cannabinoid type-2 G protein-coupled (CB2) receptor is an emerging therapeutic target for pain management and immune system modulation. In a mouse model of Alzheimer’s disease (AD) the orally administered natural product 4′-O-methylhonokiol (MH) has been shown to prevent amyloidogenesis and progression of AD by inhibiting neuroinflammation. In this commentary we discuss an intriguing link between the recently found CB2 receptor-mediated molecular mechanisms of MH and its anti-inflammatory and protective effects in AD animal models. We argue that the novel cannabimimetic MH may exert its beneficial effects via modulation of CB2 receptors expressed in microglial cells and astrocytes. The recent findings provide further evidence for a potential role of CB2 receptors in the pathophysiology of AD, spurring target validation and drug discovery.",
keywords = "Alzheimer’s disease, Cannabinoids, CB2 receptors, Endocannabinoid System, Magnolia grandiflora, Medicinal plant, Methylhonokiol",
author = "J{\"u}rg Gertsch and Sharon Anavi-Goffer",
note = "Acknowledgements We thank Stefanie Hofer-Reyes for proofreading the manuscript",
year = "2012",
month = "6",
day = "20",
doi = "10.1186/1742-2094-9-135",
language = "English",
volume = "9",
journal = "Journal of Neuroinflammation",
issn = "1742-2094",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Methylhonokiol attenuates neuroinflammation

T2 - a role for cannabinoid receptors?

AU - Gertsch, Jürg

AU - Anavi-Goffer, Sharon

N1 - Acknowledgements We thank Stefanie Hofer-Reyes for proofreading the manuscript

PY - 2012/6/20

Y1 - 2012/6/20

N2 - The cannabinoid type-2 G protein-coupled (CB2) receptor is an emerging therapeutic target for pain management and immune system modulation. In a mouse model of Alzheimer’s disease (AD) the orally administered natural product 4′-O-methylhonokiol (MH) has been shown to prevent amyloidogenesis and progression of AD by inhibiting neuroinflammation. In this commentary we discuss an intriguing link between the recently found CB2 receptor-mediated molecular mechanisms of MH and its anti-inflammatory and protective effects in AD animal models. We argue that the novel cannabimimetic MH may exert its beneficial effects via modulation of CB2 receptors expressed in microglial cells and astrocytes. The recent findings provide further evidence for a potential role of CB2 receptors in the pathophysiology of AD, spurring target validation and drug discovery.

AB - The cannabinoid type-2 G protein-coupled (CB2) receptor is an emerging therapeutic target for pain management and immune system modulation. In a mouse model of Alzheimer’s disease (AD) the orally administered natural product 4′-O-methylhonokiol (MH) has been shown to prevent amyloidogenesis and progression of AD by inhibiting neuroinflammation. In this commentary we discuss an intriguing link between the recently found CB2 receptor-mediated molecular mechanisms of MH and its anti-inflammatory and protective effects in AD animal models. We argue that the novel cannabimimetic MH may exert its beneficial effects via modulation of CB2 receptors expressed in microglial cells and astrocytes. The recent findings provide further evidence for a potential role of CB2 receptors in the pathophysiology of AD, spurring target validation and drug discovery.

KW - Alzheimer’s disease

KW - Cannabinoids

KW - CB2 receptors

KW - Endocannabinoid System

KW - Magnolia grandiflora

KW - Medicinal plant

KW - Methylhonokiol

U2 - 10.1186/1742-2094-9-135

DO - 10.1186/1742-2094-9-135

M3 - Article

C2 - 22716035

VL - 9

JO - Journal of Neuroinflammation

JF - Journal of Neuroinflammation

SN - 1742-2094

M1 - 135

ER -